It is a small molecule AMPK/mitochondrial activator for the treatment of cardiometabolic diseases, currently being studied in a phase 1b trial in pre-diabetic ... non-arteritic anterior ischemic optic ...

SAN DIEGO — Treatment with a spinal cord stimulation system reduced pain and restored sensory nerve function in a small cohort of individuals with diabetic peripheral neuropathy, according to a ...

Compared with painless diabetic neuropathy, painful diabetic neuropathy was associated with higher rates of depression and anxiety and lower quality of life. Painful diabetic peripheral neuropathy ...

"Millions of patients with diabetic neuropathy are left with limited, often ineffective treatment options," said Erez Aminov, Chairman and CEO of MIRA. "With Ketamir-2, we're aiming to offer a non ...

Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals ...

Diabetic neuropathy is the most common neuropathy in industrialized countries, and it is associated with a wide range of clinical manifestations. The vast majority of patients with clinical ...

MIRA Pharmaceuticals (MIRA) announced data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy. In the study, Type 2 diabetes was ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

(4) Denervated bands of Schwann cells. Multifocal diabetic neuropathy. Cross section of a paraffin-embedded superficial peroneal nerve specimen from a patient with a subacute progressive ...